How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism

Blood. 2019 May 23;133(21):2269-2278. doi: 10.1182/blood-2019-01-846048. Epub 2019 Mar 29.

Abstract

Anticoagulant therapy is the most effective strategy to prevent arterial and venous thromboembolism, but treating older individuals is challenging, because increasing age, comorbidities, and polypharmacy increase the risk of both thrombosis and bleeding. Warfarin and non-vitamin K antagonist oral anticoagulants are underused and often underdosed in the prevention of stroke in older patients with atrial fibrillation because of concerns about the risk of bleeding. Poor adherence to anticoagulant therapy is also an issue for older patients with atrial fibrillation and those at risk of recurrent pulmonary embolism. In this review, we present 5 clinical cases to illustrate common challenges with anticoagulant use in older patients and discuss our approach to institute safe and effective antithrombotic therapy.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Aged
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / pathology
  • Female
  • Humans
  • Male
  • Risk Factors
  • Stroke / etiology
  • Stroke / pathology
  • Stroke / prevention & control
  • Treatment Outcome
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / pathology
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin